Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:38 ET | 3110 | 0.81 |
09:50 ET | 500 | 0.8375 |
09:54 ET | 523 | 0.81 |
09:56 ET | 5000 | 0.838 |
10:28 ET | 100 | 0.82 |
10:51 ET | 1923 | 0.82 |
10:53 ET | 1999 | 0.827999 |
11:20 ET | 3001 | 0.825 |
11:29 ET | 300 | 0.825 |
11:33 ET | 100 | 0.825 |
11:38 ET | 252 | 0.825 |
11:45 ET | 601 | 0.825 |
11:51 ET | 100 | 0.815 |
11:58 ET | 100 | 0.81 |
12:23 ET | 1197 | 0.82 |
12:27 ET | 11000 | 0.812058 |
12:30 ET | 100 | 0.81 |
12:54 ET | 200 | 0.815292 |
01:14 ET | 4000 | 0.831 |
01:28 ET | 300 | 0.816789 |
01:30 ET | 5000 | 0.81021 |
01:35 ET | 3400 | 0.81021 |
02:02 ET | 622 | 0.81 |
02:11 ET | 100 | 0.81 |
02:24 ET | 30700 | 0.8201 |
02:26 ET | 600 | 0.8201 |
02:38 ET | 100 | 0.8201 |
02:45 ET | 300 | 0.823 |
03:20 ET | 100 | 0.82 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 29.5M | -3.4x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 7.4M | -0.2x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 7.7M | 0.4x | +78.05% |
CASI Pharmaceuticals Inc | 82.6M | -2.7x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $29.5M |
---|---|
Revenue (TTM) | $42.6M |
Shares Outstanding | 35.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.83 |
EPS | $-0.24 |
Book Value | $0.64 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | 0.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -22.79% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.